Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar 9;19(3):292-303.
doi: 10.1016/j.chom.2016.02.002. Epub 2016 Feb 25.

HIV-Host Interactions: Implications for Vaccine Design

Barton F Haynes  1 , George M Shaw  2 , Bette Korber  3 , Garnett Kelsoe  4 , Joseph Sodroski  5 , Beatrice H Hahn  2 , Persephone Borrow  6 , Andrew J McMichael  6
Affiliations
Review

HIV-Host Interactions: Implications for Vaccine Design

Barton F Haynes et al. Cell Host Microbe. .

Abstract

Development of an effective AIDS vaccine is a global priority. However, the extreme diversity of HIV type 1 (HIV-1), which is a consequence of its propensity to mutate to escape immune responses, along with host factors that prevent the elicitation of protective immune responses, continue to hinder vaccine development. Breakthroughs in understanding of the biology of the transmitted virus, the structure and nature of its envelope trimer, vaccine-induced CD8 T cell control in primates, and host control of broadly neutralizing antibody elicitation have given rise to new vaccine strategies. Despite this promise, emerging data from preclinical trials reinforce the need for additional insight into virus-host biology in order to facilitate the development of a successful vaccine.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Model of the HIV-1 transmission bottleneck
Mucosal transmission reduces the genetic and phenotypic diversity of the donor HIV-1 quasi-species to only one or very few variants that seed infection in the recipient. Viruses that traverse the mucosa, but are defective or fail to initiate a productive infection (i.e., have a basic reproductive ratio Ro of lower than 1), will be extinguished. In contrast, the mucosal bottleneck selects for viruses with a high transmission fitness. Although the biological properties that comprise this phenotype remain to be fully elucidated, a high replicative capacity, increased infectivity, enhanced dendritic cell interaction, and greater resistance to the antiviral effects of type 1 interferons (IFNs) are likely to contribute (Parrish et al., 2013).
Figure 2
Figure 2
Co-evolution of HIV transmitted-founder virus and evolving neutralizing antibodies. The initial transmission event of sexually transmitted HIV-1 is mediated by one transmitted founder (TF) virus. The TF virus induces an initial antibody response, called the autologous neutralizing antibody, that is specific for the TF virus. The autologous neutralizing antibody neutralizes the TF but rapidly selects virus escape mutants, which in turn induces new antibody specifities. This process is repeated throughout virus evolution such that after years of infection, a spectrum of cross-reactive neutralizing antibodies are induced, with ~20% of chronically infected individuals making high levels of very broadly reactive neutralizing antibodies.
Figure 3
Figure 3
HIV-1 trimer and Broadly Neutralizing Antibody Binding Sites. Co-crystal structure of the HIV-1 trimer (Pancera et al. 2014) with gp120 in blue and gp41 in grey. The five areas targeted by broadly neutralizing antibodies are the CD4 binding site (orange), V1V2 glycans (red), V3 glycans (green), gp120-gp41 bridging site (purple) and the membrane proximal external region (dark red). The area of insertion of the envelope trimer into the membrane is noted by the transmembrane domain and the gp160 cytoplasmic domain is noted.
Figure 4
Figure 4
Cooperation of` B cell lineages in induction of HIV-1 broadly neutralizing antibodies. The transmitted founder (TF) virus induces both a broadly neutralizing antibody (bnAb) lineage (CH103 lineage in red) as well as a second lineage (the CH235 cooperating lineage in blue). The TF directly drives the bnAb lineage while the cooperating antibody lineage selects virus escape mutants that bind to and are neutralized by the bnAb lineage. Thus, in this case, the bnAb lineage is driven both by escape mutants from other cooperating lineages.
Figure 5
Figure 5
Degrees of HIV-1 control by vaccines that elicit CD8 T cell responses: Each vaccine was designed to elicit only or primarily, T cell responses. These were the STEP Adenovirus-5-Gag-Pol-Nef vaccine (McElrath et al., 2008), DNA-Adenovirus-5 SIV Gag (Casimiro et al., 2005), DNA-Adenovirus-5-mosaic Gag (Roederer et al., 2014), Adenovirus-26 gag + Adenovirus 5 gag (Liu et al., 2009), RhCMV68-1 – SIV (Hansen et al., 2011), and ChAd63-HIVconsv – MVA-HIVconsv (Borthwick et al., 2014) vaccines. The peak responses after vaccination are shown. On the y axis is the magnitude as virus specific T cells per million PBMC (either directly from Elispot values or converted from % CD8 T cells in flow cytometry assays). On the x axis is shown the number of epitopes reported (breadth) corrected for the degree of matching between vaccine and challenge/infecting virus. For perfect matches between the vaccine and challenge the correction value is 1.0, for the STEP vaccine it is estimated to be 0.7. The left hand plot shows values for the STEP trial compared to similar vaccines in the SIV model. In the right panel these are compared to the values for the RhCMV-68.1-SIV vaccine. Also shown here are the values for the HIVconsv conserved region vaccine in a phase I trial in humans where there was no HIV-1 exposure. Where known, the outcomes of SIV challenge of HIV-1 exposure are shown.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abdul-Jawad S, Ondondo B, van Hateren A, Gardner A, Elliott T, Korber B, Hanke T. Increased valency of conserved-mosaic vaccines enhances the breadth and depth of epitope recognition. Molecular therapy: the journal of the American Society of Gene Therapy. 2016 epub ahead of print Jan 5, 2016. - PMC - PubMed
    1. Alam SM, Dennison SM, Aussedat B, Vohra Y, Park PK, Fernandez-Tejada A, Stewart S, Jaeger FH, Anasti K, Blinn JH, et al. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:18214–18219. - PMC - PubMed
    1. Andrabi R, Voss JE, Liang CH, Briney B, McCoy LE, Wu CY, Wong CH, Poignard P, Burton DR. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. Immunity. 2015;43:959–973. - PMC - PubMed
    1. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood. 2015;125:3393–3400. - PubMed
    1. Barouch DH, Alter G, Broge T, Linde C, Ackerman ME, Brown EP, Borducchi EN, Smith KM, Nkolola JP, Liu J, et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science. 2015;349:320–324. - PMC - PubMed

Publication types